The behavioral rehabilitation market is estimated to register a steady CAGR of 3.5 % during the forecast period from 2021-2026.
The COVID-19 pandemic is expected to have a slightly negative impact on the market. At present, countries across the world are facing a considerable threat of COVID-19 (coronavirus). Many pharmaceutical and biotechnological companies are focusing their R&D activities on manufacturing antiseptic products and vaccines to meet the increased demand from customers. Thus, most pharmaceutical and biotechnological companies have been focusing their R&D departments on identifying new molecules or leads for the treatment of this disease.? Many countries already approved a vaccine for COVID-19. For instance, in December 2020, the World Health Organization (WHO) issued the emergency use validation of Pfizer/BioNTech COVID-19 mRNA vaccine globally. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology in January 2021, people with mental disorders like dementia are at high risk of COVID-19 infection because cognitive symptoms cause difficulty following safeguarding procedures and living arrangements in care homes, facilitating viral spread.
Furthermore, older people with dementia are likely to have more severe disease consequences than those without dementia. As per Lewy Body Society, people with dementia and related disorders find it harder to follow government guidelines designed to prevent the spread of the virus, such as washing hands, maintaining the recommended physical distance, monitoring COVID-19 symptoms, and staying at home. People with more severe dementia may not understand or remember the guidelines due to their short-term memory loss and cognitive impairment. As per Office for National Statistics UK 2020, dementia and Alzheimer’s disease were the most common pre-existing conditions found among deaths involving COVID-19 in the United Kingdom.
Furthermore, due to the COVID-19 pandemic, many families face a significant economic burden, which can lead to an even greater inclination toward letting go of treatment options. Moreover, the pandemic can also have a negative impact on the new product launches, which are estimated to be the most prominent factor of the growth of the market. For instance, in April 2020, Biogen announced that it had delayed Alzheimer’s and dementia drug filing to FDA while citing the complexity of data analysis and impact on COVID-19 on its R&D resources.
According to the statistics provided by the Mental Health Foundation in 2018, mental health problems were one of the primary causes of rising medical concerns. Furthermore, mental and behavioral health problems are considered the primary cause of disability in the age group of 20-29 years for the past few decades. According to the same source, every year, many people were diagnosed with mental illnesses in the United States. According to the United States Department of Health and Human Services (DHHS), in 2018, one in every five (20%) children and adolescents suffer from mental health disorders at some point in their life. At least 1 in 10, or about 6 million people, suffered serious emotional disturbance at some point in their life.
The treatments for behavioral disorders mainly focus on behavioral treatment and medication. Parent management training and family therapy are considered quite effective for managing behavioral disorders. Additionally, cognitive behavioral therapy treatment is the most commonly used mechanism for managing the symptoms of behavioral disorders. However, medication treatment for these disorders targets underlying or co-occurring disorders, such as attention deficit hyperactivity disorder (ADHD), depression, or anxiety. These developments are expected to positively affect market development.
Key Market Trends
Anxiety Disorder is Expected to Significant Share of the Global Behavioral Rehabilitation Market Over the Forecast Period
Anxiety disorders are different from normal feelings of anxiousness, and they involve excessive anxiety or fear. According to Our World in Data (OWID), an estimated 284 million people experienced an anxiety disorder in 2017 globally, making it the most prevalent mental health or neurodevelopmental disorder. The Anxiety and Depression Association of America (ADAA) states that anxiety disorders are the most common mental illness in the United States, affecting 40 million adults of age 18 and older, i.e., 18.1% of the population each year. Although anxiety disorders are very much treatable, only 36.9% of those suffering receive treatment, according to the Anxiety and Depression Association of America. Individuals with an anxiety disorder are three to five times more likely to visit the doctor and six times more likely to be hospitalized for psychiatric conditions than those who do not have anxiety disorders. The roots of anxiety disorders are presently unknown but probably involve a combination of factors, including genetic, psychological, environmental, and developmental.
However, many antidepressants, including escitalopram (Lexapro) and fluoxetine (Prozac), can alleviate anxiety disorders and help people lead a normal and productive life. Furthermore, the increase in research and development on the treatment of anxiety disorders due to the increasing prevalence of this disorder are expected to drive the market growth over the forecast period.
North America is Expected to Hold the Major Share of the Market Over the Forecast Period
North America is the largest behavioral rehabilitation market globally, with the United States occupying the major share. The developed countries, including the United States and Canada, are witnessing many mental health rehabilitation centers opening for the past decade. According to the NIH, in the United States, the prevalence of personality disorders was 9.1%. As per the National Institute of Mental Health, 2018, in the United States, 21.4% of American adults experienced mood disorders at some point in their lives. It has also been found that there are various new launches in the behavioral health market in North America. For instance, in September 2019, Hackensack Meridian Health launched the first medically integrated urgent care center with behavioral health in the country to improve access, better coordinate care, and innovate treatment for people struggling with mental health issues and addictions. Therefore, favorable government initiatives and many reimbursement options are two of the other factors fueling growth in this region. The Affordable Care Act categorizes behavioral disorders as essential healthcare, which helps cover the major part of the treatments. Thus, these factors affect the growth of the market.
The market is slightly consolidated with a few major players. Currently, many companies are focusing on the development and introduction of novel products and services into the market, which is easily affordable and accessible, and entering strategic collaborations and partnerships to enhance their market positions. Some of the key innovations in the market are: In February 2019, Acadia Healthcare acquired the operations and real estate associated with Whittier Pavilion, a premier behavioral healthcare facility located in Haverhill, Massachusetts, and Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona, and Oklahoma.
The market estimate (ME) sheet in Excel format
3 months of analyst support